Preora Healthcare

Executive Summary

Preora Healthcare is a San Diego-based diagnostics company founded in 2018, pioneering non-invasive early disease detection through breath analysis. By identifying volatile organic compound (VOC) biomarkers, its platform aims to transform screening and monitoring into rapid, patient-friendly tests. The technology targets high-impact areas such as cancer, infectious diseases, and metabolic disorders, potentially enabling earlier intervention and improved outcomes. As a pre-revenue entity, Preora's progress hinges on validating its biomarker panels in clinical studies and navigating regulatory pathways. The company's approach addresses a critical need for accessible, low-cost diagnostics that can be deployed at point-of-care settings, reducing reliance on invasive procedures and expensive imaging. Looking ahead, Preora Healthcare's success depends on achieving key technical and clinical milestones. The company is likely pursuing a focused development strategy, prioritizing one or two lead indications to demonstrate proof-of-concept and attract strategic partnerships. The market for breath-based diagnostics is growing, with increasing interest from healthcare providers and payers in non-invasive screening tools. If Preora can deliver robust clinical data and secure regulatory clearance, it could capture a share of the multi-billion-dollar diagnostics market. However, the early-stage nature and lack of disclosed funding raise execution risk. Overall, the company's innovative platform and addressable market present a compelling opportunity, tempered by the uncertainties inherent in diagnostic development.

Upcoming Catalysts (preview)

• Q3 2026Completion of Pilot Clinical Study for Lead Indication (e.g., Lung Cancer Screening)60% success
• Q4 2026Strategic Partnership or Licensing Agreement with Diagnostic or Pharmaceutical Company40% success
• TBDSubmission of Pre-Submission or 510(k) to FDA for Breath Analyzer Platform30% success